Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-TLX591 + Standard of Care vs Standard of Care Alone in PSMA+ mCRPC
NCT06520345Phase 3Recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of 177lu-rosopatamab in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Telix Pharmaceuticals Limited. Primary endpoint: Radiographic Progression-free Survival at 337 days. Started Jul 2024; status: recruiting.
02
Drugs
177lu-rosopatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06520345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520345.